Abstract Dietary studies often report low calcium intake amongst post-menopausal Malaysian women and calcium deficiency has been implicated as part of the etiology of age-related bone loss leading to osteoporosis.
Introduction
In Asia osteoporosis is rapidly becoming a major public health problem, with an increasing incidence of hip fracture and a rapidly aging population [1] . Similarly, in Malaysia, the incidence of hip fractures among individuals over 50 years of age was reported to be 0.90 per 1000 people, with the highest prevalence amongst Chinese women [2] . The incidence of osteoporosis is expected to increase in view of the country's rapidly ageing population. Statistics show that the percentage of the Malaysian population aged above 65 years grows annually at a rate of 3% and it is projected that by the year 2020, there will be 7.3% or 2 million elderly people in the country [3] . Economic development and rapid urbanization in Malaysia over the past 3 decades has brought about a shift towards a more ''affluent'' diet and lifestyle, and increased prevalence of chronic diseases [4] . Therefore, osteoporosis may be expected to pose an increasing public health problem if appropriate intervention is not taken.
Calcium intake is particularly important in postmenopausal and elderly women because lack of calcium is associated with reduced bone density. Low calcium intake has been reported to be one of the risk factors for osteoporosis amongst Asian women [5] . Studies of food consumption in Malaysia over the past decade have consistently reported calcium intakes below 500 mg/day [6, 7] . Many studies have shown a beneficial effect of increased calcium intake in reducing the rate of bone loss in postmenopausal Caucasian women [8, 9, 10] . However, studies in Asian populations are few, though promising results were found in a recent study in Chinese women in Hong Kong [11] .
The Malaysian Dietary Guidelines [12] recommend obtaining adequate calcium from low-fat milk and its products and other calcium-rich food sources to prevent osteoporosis. Currently, food manufacturers in the country have also made available calcium-fortified products such as high calcium milk, yogurt, breakfast cereals, biscuits and rice. Therefore, we undertook a 2-year randomized controlled trial to study the effect of a milk supplement on bone mineral density in healthy postmenopausal Chinese women in Malaysia.
Materials and methods
The study protocol was approved by the research ethics committee of the National University of Malaysia and University Malaya Medical Center. All subjects provided written informed consent.
Subjects
Volunteers were invited by advertisements and subject recruitment was also conducted in various senior citizens clubs, residential areas and religious centers within a 50 km radius of Kuala Lumpur. Respondents were initially screened for eligibility by using a questionnaire. Chinese women who were aged between 50 and 65 years and more than 5 years postmenopausal were eligible for the study. Subjects were excluded if they had a history of bone disease or medical conditions that affect bone metabolism, if they were taking medications that affect bone metabolism (e.g. hormone/estrogen replacement therapy, thiazide diuretics, glucocorticoids) or had other chronic illnesses (such as diabetes, kidney disease, heart disease, or cancer). Women taking calcium supplementation (>500 mg/day) for longer than a month or were already drinking 2 or more glasses of milk a day were also excluded.
Randomization and treatments
The screening yielded 226 eligible individuals, of whom 200 provided informed consent, underwent random assignment and completed their baseline measurements. The subjects were randomly assigned to the intervention or non-intervention groups by permuted block randomization. The intervention group received 50 g of high-calcium skimmed milk powder (Anlene Goldä, New Zealand Milk, Wellington, New Zealand) which they reconstituted with 400 ml water and consumed daily for 24 months. The nutrient composition of the 50 g milk powder is as follows: calcium 1200 mg, calories 170 kcal, protein 17.8 g, carbohydrate 25.2 g, fat 0.4 g, phosphorus 750 mg, magnesium 70 mg and vitamin D 3 10 lg. The non-intervention group continued with their usual diet and did not receive any placebo. All subjects were asked to maintain their physical activity and dietary patterns throughout the study. The subjects in the milk group had been given advice to adjust their energy intake to compensate for the additional calories provided by the milk.
Measurements
At baseline, subjects were interviewed about their demographic and socioeconomic background, past medical history, reproductive history, fracture history (self and family members), current and past physical activity level, smoking and alcohol use, and milk and calcium supplementation use, using a questionnaire. At baseline and 6-monthly thereafter, subjects underwent measurement of weight, height and bone mineral density, provided fasting blood and urine samples, and 3-day food records.
Measurements of bone mineral density (BMD) were undertaken by dual-energy X-ray absorptiometry (DXA; Lunar DPX-L, Madison, Wisc., USA) with the analysis software version 3.1. A daily quality assurance check using the aluminum spine phantom provided by the manufacturer was carried out. The CVs for BMD measurements were 1.3% at the femoral neck, 1.7% at the total hip, 1.5% at the spine and 0.3% at the total body. Bone density scans (hard copy and quality files) were sent to Auckland University for external quality assurance checks.
Subjects' weight and height were measured, in light clothing and no shoes, using a digital balance (SECA, Germany) with height attachment, to the nearest 100 g and 0.1 cm, respectively. The body mass index was calculated as weight/height 2 . Lean body mass and body fat were also measured by DXA.
Dietary intake was measured using 3-day food records for overall nutrient intake including energy, protein and calcium. A validated Food Frequency Questionnaire was administered at baseline, 12 and 24 months. Nutrient content was calculated based on the Malaysian Food Composition Table [13] .
A fasting venous blood sample was collected from each subject between 0900 and 1000 hours at each visit. Second-void urine samples were collected from all subjects between the hours of 0830 and 0900 hours. Serum calcium, phosphate, magnesium and alkaline phosphatase as well as urinary calcium, sodium and creatinine were measured using the Dimension Clinical Chemistry System (Dade International Inc., Deerfield, Ill., USA). Intact parathyroid hormone (hPTH 1-84) was measured by immunoradiometric assay (IRMA) using the DiaSorin N-tact PTH SP IRMA kit (DiaSorin Inc., Minn., USA). The inter-assay CV for PTH measurement was 15%. Intact osteocalcin was measured using NovoCalcin kit (Metra Biosystems Inc., Calif., USA). The inter-assay CV for osteocalcin was 9.3%. Urine deoxypiridinoline (Dpd) level was measured using the ACS:180 Automated Chemiluminescent Immunoassay System (Chiron Diagnostics Corp., Mass., USA). The DPD concentration was calculated as Dpd/creatinine ratio (nM/mM). The inter-assay CV was 10%. A liquid phase radioimmunoassay kit (Gamma B, IDS Ltd, USA) was used for extraction and quantification of 25-hydroxyvitamin D in serum. The interassay CV was 7-9%.
Compliance
Subjects were required to record the number of milk sachets consumed every day. Compliance rate was calculated as percentage of actual consumption over expected consumption each month. The investigators also randomly made home visits or contacted by telephone 10% of the subjects every month to check the number of sachets remaining at each point of time. Subjects who initially had problems ingesting 2 glasses of the reconstituted milk a day were asked to start with 1 glass and gradually increased intake to 2 within the shortest time possible.
Statistical analysis
Statistical analysis was performed on the 173 women who completed the 2-year trial. Differences in baseline characteristics between treatment groups were compared by t-test. Differences between groups at each year of follow-up were compared by repeated measures analysis of co-variance with baseline values as a covariate and time as the repeated measure. Within group differences were compared by repeated measures ANOVA with time as the repeated measure. All P-values are two-tailed. The Statistical Package for Social Sciences (SPSS) software version 10.0 (SPSS Inc., Chicago, USA) was used for the data analyses.
Results

Drop-outs and compliance rate
Twenty-seven of the 200 volunteers dropped out from the study, thus 173 subjects (91 milk, 82 control) completed the trial yielding a total dropout rate of 13.5%. Twenty-one subjects dropped out during the first 6 months of the study. In the control group, ten subjects withdrew because they lost interest in the study and were unhappy that they were not receiving any milk supplement. Four subjects moved out of Kuala Lumpur, one subject started taking HRT, one subject had cancer and two others cited personal reasons for dropping out.
In the milk supplement group, a total of nine subjects dropped out from the study. Five of the subjects disliked the milk and refused to continue in the study, after taking the milk for several weeks. Other reasons for dropping out from the supplemented group were serious illness (one subject), moved away from Kuala Lumpur (two subjects) and personal reasons (one subject). The overall mean compliance rate for taking the milk supplement amongst those who remained in the trial was 92.0±7.9% with a range of 64-100%.
Baseline characteristics
The 173 participants who completed the trial had an average age of 59±3 years (range 55-65 years), time since menopause was 9±4 years (range 5-23 years), body mass index was 23.8±3.6 kg/m 2 , and daily calcium consumption was 473±221 mg/day (from 3-day food records). Table 1 showed that no significant differences between groups were found for age, time since menopause, anthropometric measurements, dietary calcium intake, physical activity level and several biochemical parameters. However, the milk group had lower baseline bone mineral density at the total body (P<0.01), femoral neck (P<0.001) and total hip (P<0.001) compared to the control group, though the absolute differences were small. These differences, however, were controlled as covariates when comparing percentage changes in BMD between groups.
Anthropometry and bone mineral density changes
The results showed that the milk and control groups maintained their weight and height after 24 months. Changes in body fat percentages and lean body mass were also not significant. Table 1 and Fig. 1 show that supplementation of high calcium milk significantly reduced the percentage of bone loss at the total body compared to the control group (P<0.001). At the lumbar spine, the percentage of bone loss in the milk group was also significantly lower (P<0.05) than the control group. Similarly, milk supplementation reduced the percentage of bone loss at the femoral neck (P<0.01) and total hip (P<0.01). At all sites, the control group experienced significant bone loss over time compared to baseline while bone density was maintained in the milk-supplemented group.
PTH and bone turnover markers Figure 2 shows the changes in mean PTH, serum osteocalcin and urinary deoxypiridinoline levels at baseline, 12 and 24 months. The serum PTH levels of the control group increased significantly with time and were significantly higher than those in the milk group at 2 years (P<0.05). The PTH levels in the milk supplemented group did not change significantly with time at 24 months. The mean percentage change in bone resorption, as reflected by urinary Dpd/creatinine ratio excretion, was not significantly different between groups. Mean changes in bone formation, as reflected by the serum osteocalcin levels, also showed no significant difference between groups at 12 and 24 months.
Dietary intake and serum 25-hydroxy vitamin D concentration
At 12 months follow-up, mean daily calcium intake had increased significantly over the baseline in the milk supplemented group, and this increase persisted throughout the study (Table 2 ). In contrast, dietary calcium consumption for the control group did not change significantly over the course of the study. The mean total daily calcium intake in the milk supplemented group ranged from 1524 mg/day at 12 months to 1548 mg/day at 24 months while the mean calcium intake in the control group remained at below 500 mg/day. The control group significantly reduced their energy intake with a corresponding reduction in protein (66±17-59±18 g/day) and carbohydrate intakes (207±43-190±47 g/day) at 24 months of follow-up. Fat intake however, was not significantly different from baseline. In the milk supplemented group, energy, carbohydrate and fat intake did not change significantly from baseline but protein intake was significantly higher at 24 months compared to the control group. Table 3 shows that the mean serum 25-hydroxyvitamin D level of the control group was not significantly different from baseline. However, mean serum concentrations of vitamin D increased significantly in the milk supplemented group from baseline to both 12 and 24 months of the study (P<0.01).
Discussion
This study shows that high calcium milk supplementation for 24 months is effective in retarding bone loss at the total body, lumbar spine and hip regions including femoral neck and total hip. In contrast to the large number of clinical trials using calcium supplements, there are very few clinical trials using milk in postmenopausal women. Milk supplementation has been previously studied in premenopausal women, where it has been shown to be effective in slowing bone loss [14] . Prince et al. [10] and Storm et al. [15] found that elderly women given milk supplements experienced less bone loss at various bone sites compared to control or placebo groups. The study by Lau et al. [11] is, as far as we are aware, the only other study using milk powder supplements in an Asian population. The results of the present study support the conclusion by Lau et al. [11] that high calcium milk is effective in preventing bone loss in postmenopausal Asian women. This study showed that the mechanisms by which milk supplementation prevented bone loss in postmenopausal women were associated with suppression of PTH levels. We observed a higher level of PTH in the control group than the milk supplemented group at the end of 24 months. Other calcium supplementation studies have also shown an age-related increase in PTH levels in the control or placebo group with time while calcium and milk supplementation reduced the serum PTH levels [11, 16, 17] . However, the study was unable to detect any significant changes in bone formation and resorption markers between the milk and control groups. A possible explanation is that the precision of these biochemical markers is not sufficient to detect the difference in bone turnover in this number of women. The substantial effects of the intervention on PTH levels and BMD make it very likely that there is also an effect on turnover. An earlier study by Prince et al. [10] also reported no significant difference in deoxypyridinoline (Dpd) markers for milk powder or calcium tablets and placebo groups at the end of 2 years of supplementation. Studies which measured biochemical indexes at shorter time periods e.g. within 48 h have shown that evening calcium supplementation reverses the nocturnal increase in PTH and reduces overall daily bone resorption as measured by Dpd and NTx [18] . Milk supplementation has also been shown to produce similar reduction in PTH levels and bone resorption as measured by NTx at 8 weeks after supplementation [19] . A recent study by Jensen et al. [20] on the long term effects of calcium supplementation on bone turnover markers and calciotropic hormones reported a reduction at 1 year but reversion towards baseline values thereafter. They have suggested that the loss of suppression over time may be the reason why nutrient intervention is less effective than the active medications such as estrogen and biphosphonates in reversing bone resorption.
This study showed that the addition of milk to the diet of postmenopausal women with low calcium intakes resulted in an overall dietary improvement and no undesirable consequences such as weight gain. Lau et al. [11] reported a significant increase in weight of 0.5 kg in the milk-supplemented group compared to control. Heaney et al. [19] showed that milk supplements induced a weight gain of about 0.7 kg during the first month of intervention, but after 12 weeks, no significant weight changes were noticed compared to controls, presumably because the subjects adjusted their total food intake appropriately.
It is not possible to conclude whether the calcium content of the milk or the combined effect of its nutritional components caused the beneficial effect seen in reducing the rate of bone loss. The milk used contained several nutrients known to be beneficial for bone health such as protein, vitamin D 3 , phosphorus, magnesium and zinc. The milk supplement also improved the serum 25-hydroxyvitamin D concentrations in the subjects over the 2 years. A similar improvement in vitamin D status from ingestion of milk powder was also reported by other studies [11, 19] . The improved vitamin D status may have played a role in suppressing parathyroid hormone levels and thus in maintaining the BMD of these subjects.
In conclusion, the results of this study indicate that consuming high calcium skimmed milk was beneficial in slowing down bone loss in postmenopausal Chinese women in Malaysia, at clinically important lumbar spine and hip sites. Such dietary changes, if sustained over the long term, may be a useful public health measure to reduce osteoporosis in Malaysia.
